問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

姜乃榕

Recruiting

List

99Cases

2023-02-01 - 2026-05-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-05-31 - 2031-04-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2025-07-01 - 2026-04-27

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-10-01 - 2021-03-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated1Sites

白禮源
China Medical University Hospital-Taipei

未分科

2025-07-15 - 2029-11-13

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2026-03-04 - 2034-03-11

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-06-30 - 2029-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-04-01 - 2028-01-31

Phase I

Active
A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors

  • Condition/Disease

    Advanced/Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting8Sites

Terminated1Sites

2019-02-01 - 2019-12-25

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2018-10-01 - 2022-12-31

Phase II

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

  • Condition/Disease

    Nasopharyngeal Carcinoma

  • Test Drug

    Pembrolizumab (MK3475)

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

1 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB